Prognostic implications of the bromodeoxyuridine labeling index of human gliomas
Authors:
- Michael PradosMPMichael Prados
- Charles B. WilsonCWCharles B. Wilson
- Kyung Gi ChoKCKyung Gi Cho
- Kyu-Sung LeeKLKyu-Sung Lee
- Richard L. DavisRDRichard L. Davis
- 1 September 1989
- journal article
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery
- Vol. 71 (3) , 335-341
Abstract
✓ This study includes 182 patients with intracranial gliomas who received bromodeoxyuridine (BUdR), 200 mg/sq m intravenously, at the time of craniotomy but before tumor biopsy. The tumor specimens were stained for BUdR using the immunoperoxidase method; the BUdR labeling index (LI), or S-phase fraction, was calculated as the percentage of BUdR-positive cells. The median BUdR LI's for 127 primary moderately anaplastic astrocytomas, highly anaplastic astrocytomas, and glioblastomas (< 1%, 2.7%, and 7.3%, respectively; range 0% to 38.1%) were not significantly different from those of 55 similar recurrent tumors (< 1%, 4.3%, and 7.4%, respectively; range 0% to 30.5%). The mean LI was significantly higher in tumors from patients over 50 years of age than in tumors from younger patients (p < 0.001). This age-related difference in LI's was found in both groups of patients with astrocytomas but not in those with glioblastomas. Kaplan-Meier survival curves showed a significantly greater probability of survival among patients whose tumors had LI's of less than 1% than among those with LI's greater than 5%; survival probability of patients with tumor LI's of 1% to 5% was intermediate between the two extremes. Thus, the BUdR LI appears to reflect the proliferative potential more accurately than the histopathological diagnosis and should therefore be considered an important factor in determining the prognosis of individual patients with intracranial gliomas and in selecting their treatment.Keywords
This publication has 24 references indexed in Scilit:
- Prognostic implications of the proliferative potential of low-grade astrocytomasJournal of Neurosurgery, 1988
- Observations on the current treatment of low-grade astrocytic tumors of the cerebral hemispheresJournal of Neurosurgery, 1987
- Improved high-affinity monoclonal antibody to lododeoxyuridineCytometry, 1986
- S‐phase fraction of human brain tumors in situ measured by uptake of bromodeoxyuridineInternational Journal of Cancer, 1986
- In situ cell kinetics studies on human neuroectodermal tumors with bromodeoxyuridine labelingJournal of Neurosurgery, 1986
- Neurosurgical management of low-grade astrocytoma of the cerebral hemispheresJournal of Neurosurgery, 1984
- Monoclonal Antibody to 5-Bromo- and 5-Iododeoxyuridine: A New Reagent for Detection of DNA ReplicationScience, 1982
- Optimal therapy in medulloblastomaActa Neurochirurgica, 1979
- Medulloblastoma.Treatment results and effect on normal tissuesCancer, 1979
- Cerebellar Medulloblastoma.Results of a new method of radiation treatmentCancer, 1979